Börse von finanzen.net | Aktien-Nachrichten | Marktberichte

DAX	6.050	-3,4%	Dow	12.119	-2,2%	Euro	1,2432	0,6%
ESt50	2.069	-2,4%	Nas	2.748	-2,8%	Öl	98,82	-2,8%
TDax	730,9	-2,7%	Nikkei	8.440	-1,2%	Gold	1.626	4,2%

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Depot
Times + Sales	Chart-Analyse	Analysen	Dividende/HV	Profil	Optionsscheine	Watchlist
Börsenplätze	Chartvergleich	Kursziele		Insidertrades	Knock-outs	myHome
Orderbuch	Realtime Stuttgart	RSS Feed		im Forum	Fonds	Senden
Historisch	Realtime Push	myNews neu		IR-Daten	Anleihen	handeln

31.05.12	BioAlliance Pharma: Combined Shareholders Meeting
29.05.12	BioAlliance Pharma SA : Receivability of Sitavig® US Registration Dossier (NDA) for the Treatment of Recurrent Orofacial Herpes Validated by the FDA
14.05.12	BioAlliance Pharma SA: Initiation of ReLive, phase III clinical trial with Livatag® In primary liver cancer
10.05.12	BioAlliance Pharma: Disclosure of total number of voting rights and number of shares in the capital at April 30, 2012
26.04.12	BioAlliance Pharma Announces Two New Key Steps in the Development of Its AMEP® Biotherapy
25.04.12	BioAlliance Pharma: Combined Ordinary and Extraordinary General Meeting on May 31, 2012
25.04.12	BioAlliance Pharma :Publication of the 2011 Registration Document
17.04.12	BioAlliance Pharma: Full-Year Financial Results for 2011
17.04.12	BioAlliance Pharma Announces: New Achievements in Clonidine Lauriad™ Clinical Development, Second Product of Its Orphan Oncology Portfolio
10.04.12	BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at March 31, 2012

20.03.12	BioAlliance Pharma: Success of the first BioAlliance Pharma’s symposium « Oncology: key issues for the future »
07.03.12	BioAlliance Pharma: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at February 29, 2012
09.02.12	BioAlliance Pharma: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at January 31, 2012
01.02.12	To Gain a Better Understanding of the Company, Its Product Portfolio and Its Management Team, BioAlliance Pharma Organizes a Symposium "Oncology: Key Issues for the Future"
26.01.12	2011 Achievements and 2012 Prospects BioAlliance Pharma Confirms the Dynamics of Its Core Business
23.01.12	BioAlliance Pharma Announces Two Key Steps with Its AMEP™ Biotherapy for Metastatic Melanoma
06.01.12	BioAlliance Pharma: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at December 31, 2011
04.01.12	BioAlliance Pharma: New Achievements in the Collaboration with Its Strategic European Partner, Therabel
08.12.11	Hasbro Announces Quarterly Cash Dividend on Common Shares
08.12.11	BioAlliance Pharma: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at November 30, 2011
18.11.11	BioAlliance Pharma Ranked as France's Fastest Growing Company in the 2011 « Deloitte Technology Fast 50 »
14.11.11	BioAlliance Pharma Reports Its Consolidated Turnover for Q3
09.11.11	BioAlliance Pharma: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at October 31, 2011
09.11.11	Jack in the Box® Holiday Elves Raise Funds for Big Brothers Big Sisters
02.11.11	BioAlliance Pharma announces: Grant of « orphan designation » for clonidine Lauriad™ in Europe
05.10.11	BioAlliance Pharma: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at September 30, 2011
05.10.11	BioAlliance Pharma: A major step forward in the development of Sitavir®: European registration file submission for the treatment of recurrent orofacial herpes
21.09.11	BioAlliance Pharma SA: Consolidated accounts for the first semester of 2011 And recent significant key events
21.09.11	Pebblebrook Hotel Trust Announces Exercise of Underwriters’ Overallotment Option and Subsequent Closing of Public Offering of 8.00% Series B Cumulative Redeemable Preferred Shares
13.09.11	BioAlliance Pharma announces positive preliminary phase I clinical results with its AMEP® biotherapy for metastatic melanoma
12.09.11	BioAlliance Pharma Announces Participation in the Midcap Event on September 22 and 23, 2011
08.09.11	BioAlliance Pharma: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at August 31, 2011
08.09.11	The Washington Post Company Declares Regular Quarterly Dividend; Announces Stock Repurchase Authorization
07.09.11	BioAlliance Pharma Announces 2 Key Decisions
05.09.11	BioAlliance Pharma: Presentation of Livatag® survival results at the international liver cancer congress in Hong Kong
08.08.11	CBL Properties and Horizon Group Properties Declare Grand Opening of The Outlet Shoppes at Oklahoma City a Success
08.08.11	BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at July 31, 2011
01.08.11	BioAlliance Pharma Initiates the Clinical Batches Production of Livatag® (Doxorubicin Transdrug™) for its Phase III Clinical Trial
28.07.11	Q2 2011: BioAlliance Pharma Accelerates the Progress of Its "Orphan Oncology Products” Portfolio and Pursues Its International Partnerships on Its "Specialty Products”
26.07.11	Successful capital increase for BioAlliance Pharma

Finanzen.net

Bioalliance PharmaAct Nom Cat-P- Aktie [WKN: A0HMXA / ISIN: FR0010095596]

Hinweis

Newssuche

ALLE Nachrichten zur Bioalliance PharmaAct Nom. Cat-P-

Anzeige

ANZEIGE